Biocartis Appoints Ben Svarczkopf As Senior Vice President Of Global Marketing To Strengthen Commercial Leadership

Biocartis Group of Companies, a precision oncology company focused on advancing personalized cancer care, has appointed Ben Svarczkopf as Senior Vice President of Global Marketing, effective June 17, 2025. In his new role, Mr. Svarczkopf will join the company’s leadership team and take charge of global marketing strategy, product management, and market access initiatives. His work will be key to driving commercial growth, boosting brand visibility, and expanding the reach of Biocartis’ oncology solutions in markets worldwide.

Mr. Svarczkopf brings over 25 years of experience in clinical laboratory science, marketing, and strategic leadership. Before joining Biocartis, he led global strategic marketing at Diasorin Molecular, where he oversaw strategic planning for clinical diagnostics and the Luminex life sciences platforms. His previous roles include Vice President of Product Innovation and Global Marketing at Cepheid (a Danaher company), as well as senior marketing and sales leadership positions at Luminex, QIAGEN, Roche Diagnostics, and Beckman Coulter.

Roger Moody, Chief Executive Officer of Biocartis, stated, “We are thrilled to welcome Ben Svarczkopf to Biocartis as our new SVP Global Marketing. His impressive track record across some of the molecular diagnostic industry’s most respected companies makes him an ideal addition to our team. Ben’s expertise will be instrumental in driving our strategic growth and advancing our mission to improve access to fast, actionable oncology testing worldwide.”

He holds a Master of Science in Biotechnology Enterprise & Entrepreneurship and Regulatory Science from Johns Hopkins University, and earned dual Bachelor of Science degrees in Medical Technology/Clinical Lab Science and Organizational Behavior from Purdue University. Mr. Svarczkopf’s appointment marks a significant step in Biocartis’ efforts to strengthen its global presence and expand adoption of its precision oncology solutions. His extensive background in both science and commercial strategy will help guide the company’s next phase of growth.